The Most Important Advancement in Resuscitation seen in Decades An approval by the U.S. Food and Drug Administration (FDA) granting the marketing of ResQCPR System is set to become the most important advancement in Resuscitation seen in decades. First Response Australia has been a distributor for the ResQCPR System since 2007 and includes this as a standard of care in its approved Paramedical Service. The technology, which has been shown to improve the likelihood of survival in adult patients with non-traumatic cardiac arrest, has been available in Australia and Europe for many years, but not in the US. This recent approval in the US now validates the many years of research and clinical trials. ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, today announced that the company's ResQCPR System has been granted premarket approval by the U.S. Food and Drug Administration (FDA) to market and begin U.S. distribution of the CPR adjunct system. A pivotal study evaluating the ResQCPR System, known as the ResQTRIAL, which the FDA considered in its approval process, demonstrated a 49% increase in one year survival for adult patients who experienced out-of-hospital cardiac arrest of presumed cardiac etiology, as compared to treatment with conventional manual CPR. If widely implemented, the ResQCPR System could save thousands of lives each year in the U.S. from out-of-hospital cardiac arrest alone, based on these study results. The ResQCPR System uses Intrathoracic Pressure Regulation (IPR), a proprietary, non-invasive therapy developed by Advanced Circulatory Systems, Inc. of Roseville, Minneapolis US., which ZOLL acquired in January 2015. This innovative technology uses the body's own mechanisms to enhance circulation without the use of pharmaceutical or other agents. The ResQCPR System is comprised of the ResQPOD Impedance Threshold Device and the ResQPUMP Active Compression-Decompression CPR Device, which work synergistically to improve perfusion.